

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The interview was conducted on May 15, 2008 and attended by Examiner Bouchelle and Applicants' representative, Laura Johnson.

Exhibits and/or Demonstrations

Demonstration of the continuous glucose sensor system conducted.

Identification of Claims Discussed

Claims 15, 25, 29, 32 and 34.

Identification of Prior Art Discussed

U.S. Patent No. 5,569,186 to Lord et al.; U.S. Patent No. 6,083,523 to Dionne et al.; U.S. Patent No. 5,507,288 to Bocker et al., PCT International Publication No. WO 97/01986 to Joseph; U.S. Patent No. 6,558,320 to Causey, III et al.; and U.S. Patent No. 6,175,752 to Say.

Proposed Amendments, Arguments and Results

Regarding Claim 15, Applicants' representative argued that Lord does not disclose the receiver 14 being physically detachably connectable to the pump 22. Examiner agreed, but stated that further search may be required.

Regarding Claim 25, Applicants' representative argued that Lord in view of Dionne would render Lord unsuitable for its intended use because beta islet cells delivered via the pump disclosed by Lord would be rejected by the body. Examiner requested that Applicants put their arguments on the record.

Applicants' representative proposed to amend Claim 29 to recite an integrated, "wherein the receiver is configured and arranged to calculate an amount of a medicament to delivery via the medicament delivery device using a glucose concentration measured by the single point glucose monitor." Examiner agreed that the proposed amendment appeared to overcome the prior art, including Bocker, Joseph, Causey and Say, however further search and consideration may be required.

Appl. No. : **10/789,359**
Filed : **February 26, 2004**

Applicants' representative proposed to amend Claim 32 to recite a system "configured to validate the medicament delivery instructions responsive to data obtained from a single point glucose monitor operably connectable to the receiver." Examiner agreed that the proposed amendment appeared to overcome the prior art, including Bocker, Joseph, Causey and Say, however further search and consideration may be required.

Applicants' representative proposed to amend Claim 34 to recite a an integrated system "configured to determine a host's metabolic response to the medicament delivery by evaluating the sensor data points substantially corresponding to delivery and release of the medicament delivery for the first time period, wherein the processor comprises programming configured to estimate glucose values responsive to glucose sensor data and host's metabolic response." Examiner agreed that the proposed amendment appeared to overcome the prior art, however further search and consideration may be required.